Precision BioSciences prices 10.24M shares at $7.75 in underwritten offering
Precision BioSciences (DTIL) priced 10.24M shares at $7.75 each, raising ~$125M before expenses. Proceeds will fund R&D for PBGENE-HBV and PBGENE-DMD, plus general corporate purposes. The offering is expected to close by November 6, 2026, with TD Cowen and Guggenheim Securities as joint book-runners.
How this was made
The 30-second read
Why it matters
The capital raise provides needed funding for R&D but introduces dilution, likely causing short‑term price weakness.
Market read
Primary disclosure of a $125 M equity raise for a micro‑cap biotech, likely prompting immediate price reaction.
What to watch
Investor appetite for biotech raises remains strong; the offering includes pre‑funded warrants which may mitigate dilution.
Background
Precision BioSciences (DTIL) is a gene‑editing company developing therapies for HBV and DMD. The offering includes both common shares and pre‑funded warrants.
Ticker impact
Precision BioSciences announced pricing of a $125 million underwritten equity offering at $7.75 per share.
downward pressure as the market prices in dilution from the $125 M raise
Primary disclosure of a sizable capital raise for a micro‑cap biotech typically triggers a sell‑off due to dilution concerns.
Market effects
Adds cash to the gene‑therapy pipeline, may boost biotech sector sentiment if the raise funds promising programs.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
The infusion of $125 M could accelerate pipeline progress, potentially outweighing dilution concerns.
Key entities
- CompanyPrecision BioSciences
Biotech firm conducting gene‑editing trials.
- UnderwriterTD Cowen
Joint book‑running manager for the offering.
- UnderwriterGuggenheim Securities
Joint book‑running manager for the offering.
